Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection.
The earliest immune responses activated in acute human immunodeficiency virus type 1 infection (AHI) exert a critical influence on subsequent virus spread or containment. During this time frame, components of the innate immune system such as macrophages and DCs, NK cells, beta-defensins, complement and other anti-microbial factors, which have all been implicated in modulating HIV infection, may play particularly important roles. A proteomics-based screen was performed on a cohort from whom samples were available at time points prior to the earliest positive HIV detection. The ability of selected factors found to be elevated in the plasma during AHI to inhibit HIV-1 replication was analyzed using in vitro PBMC and DC infection models. Analysis of unique plasma donor panels spanning the eclipse and viral expansion phases revealed very early alterations in plasma proteins in AHI. Induction of acute phase protein serum amyloid A (A-SAA) occurred as early as 5-7 days prior to the first detection of plasma viral RNA, considerably prior to any elevation in systemic cytokine levels. Furthermore, a proteolytic fragment of alpha-1-antitrypsin (AAT), termed virus inhibitory peptide (VIRIP), was observed in plasma coincident with viremia. Both A-SAA and VIRIP have anti-viral activity in vitro and quantitation of their plasma levels indicated that circulating concentrations are likely to be within the range of their inhibitory activity. Our results provide evidence for a first wave of host anti-viral defense occurring in the eclipse phase of AHI prior to systemic activation of other immune responses. Insights gained into the mechanism of action of acute-phase reactants and other innate molecules against HIV and how they are induced could be exploited for the future development of more efficient prophylactic vaccine strategies.
Kramer
Holger B
HB
Henry Wellcome Building for Molecular Physiology, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, Oxfordshire, United Kingdom.
Lavender
Kerry J
KJ
Qin
Li
L
Stacey
Andrea R
AR
Liu
Michael K P
MK
di Gleria
Katalin
K
Simmons
Alison
A
Gasper-Smith
Nancy
N
Haynes
Barton F
BF
McMichael
Andrew J
AJ
Borrow
Persephone
P
Kessler
Benedikt M
BM
D016915:AIDS Vaccines / Q000276:immunology; D000208:Acute Disease; D000209:Acute-Phase Proteins / Q000378:metabolism*; D015658:HIV Infections / Q000097:blood / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D020783:Matrix Metalloproteinase 7 / Q000097:blood / Q000494:pharmacology; D010446:Peptide Fragments / Q000097:blood* / Q000378:metabolism; D000685:Serum Amyloid A Protein / Q000378:metabolism*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D053719:Tandem Mass Spectrometry; D014766:Viremia / Q000097:blood / Q000276:immunology; D000515:alpha 1-Antitrypsin / Q000097:blood / Q000378:metabolism*
D016915:AIDS Vaccines; D000209:Acute-Phase Proteins; D010446:Peptide Fragments; C521404:SAA1 protein, human; D000685:Serum Amyloid A Protein; C519920:VIRIP peptide, human; D000515:alpha 1-Antitrypsin; D020783:Matrix Metalloproteinase 7
FASEB J. 2001 Jan;15(1):115-122
11149899
Am J Reprod Immunol. 2008 Jan;59(1):27-34
18154593
AIDS. 2003 Sep 5;17(13):1871-9
12960819
Immunity. 2007 Sep;27(3):406-16
17892849
Eur J Biochem. 1999 Oct;265(2):501-23
10504381
Clin Chem. 2005 Jan;51(1):47-55
15364884
J Allergy Clin Immunol. 2008 Jul;122(1):3-9; quiz 10-1
18468671
Hepatology. 2006 Dec;44(6):1626-34
17133472
Clin Chem. 1993 Feb;39(2):293-7
8381732
Cancer Res. 2004 Dec 1;64(23):8657-65
15574774
Nat Genet. 2002 Aug;31(4):429-34
12134147
Trends Mol Med. 2007 Nov;13(11):449-59
18029231
Biochem Biophys Res Commun. 2006 May 5;343(2):617-22
16554023
J Immunol. 2006 Jul 15;177(2):782-6
16818731
Mol Cell Proteomics. 2008 Nov;7(11):2215-28
18596065
J Virol. 2007 Jun;81(11):6128-33
17329325
Anal Biochem. 1984 Apr;138(1):141-3
6731838
Cell. 2007 Apr 20;129(2):243-5
17448985
Atherosclerosis. 2009 Dec;207(2):374-83
19535079
J Immunol. 2007 Jan 1;178(1):407-15
17182579
Scand J Infect Dis. 1986;18(5):389-94
3095915
Cell. 2007 Dec 14;131(6):1059-71
18083097
Curr Top Microbiol Immunol. 2006;306:199-230
16909923
Blood. 1997 Aug 1;90(3):1141-9
9242546
Cell. 2000 Sep 1;102(5):647-55
11007483
Nat Rev Immunol. 2010 Jan;10(1):11-23
20010788
J Infect Dis. 2003 Oct 15;188(8):1205-8
14551891
Rapid Commun Mass Spectrom. 2006;20(14):2074-80
16773668
Nature. 2005 Apr 28;434(7037):1093-7
15793563
J Virol. 2008 Aug;82(15):7700-10
18508902
J Immunol. 2006 Nov 15;177(10):6588-92
17082569
AIDS Res Hum Retroviruses. 2006 Aug;22(8):757-62
16910831
Science. 2007 Aug 17;317(5840):944-7
17641165
J Biol Chem. 1993 Nov 25;268(33):24887-91
8227051
J Oral Pathol Med. 2006 Oct;35(9):530-9
16968233
J Virol. 2009 Apr;83(8):3719-33
19176632
J Immunol. 2006 Sep 15;177(6):4072-9
16951371
Biochem J. 1998 Sep 15;334 ( Pt 3):489-503
9729453
Clin Exp Immunol. 1982 Dec;50(3):503-6
7165997
Int Rev Immunol. 2009;28(1):20-48
19241252
Biochemistry. 1999 Sep 14;38(37):12174-9
10508422
J Proteome Res. 2008 Oct;7(10):4446-54
18707157
Virus Res. 2007 May;125(2):119-34
17258834
Cell. 2007 Apr 20;129(2):263-75
17448989
Clin Diagn Lab Immunol. 2001 Sep;8(5):937-42
11527807
Biochim Biophys Acta. 1994 Mar 2;1199(2):224-8
8123672
Biochemistry (Mosc). 2006 Oct;71(10):1051-9
17125452
Nature. 2005 Apr 28;434(7037):1148-52
15793562